Saga University

Ohara Pharmaceutical Co., Ltd.

Hiroshi Ureshino

Shinya Kimura

Kazuharu Kamachi

Yuki Kurahashi

Tatsuro Watanabe

[Problems] The object is to provide a compound as a therapeutic or prophylactic agent for TKI-resistant CML to replace the injection “Dacogen®” which has been clinically used as a therapeutic agent for high-risk myelodysplastic syndrome and acute myeloid leukemia. The said compound has remarkable stability against cytidine deaminase, a hydrolytic enzyme, and is absorbed in vivo even by oral administration, incorporated into the biosynthesis route of nucleic acid, and exhibits the effect of inhibiting DNA methyltransferase (DNMT). [Solutions] A prophylactic or therapeutic agent for TKI-resistant CML, comprising a compound represented by formula (I) or a salt thereof, wherein Rand Rare each independently a hydrogen atom or a silyl group represented by formula (II): wherein R, R, and Rare each independently an alkyl group which may have a substituent, an aryl group which may have a substituent, or an arylalkyl group which may have a substituent, with the provision that the case where both Rand Rare hydrogen atom is excluded.

Growing community of inventors

Saga, Japan

Hiroshi Ureshino